RxDoctor Payments Data

Alison Smith

Family · Manchester, MDNPI 1639894561

Payments from drug & device makers

$481in general payments, 2019–2025

Across 24 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$246
  • Pfizer$51
  • Novo Nordisk$38
  • Lilly USA, LLC$32
  • Indivior Inc.$30
  • Sumitomo Pharma America, Inc.$28
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$481 in reported general payments places this provider in the 55th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$66,003
Medicare patients
274
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$28,938
EliquisApixaban23$16,095
MounjaroTirzepatide11$11,247
Ezetimibe25$3,249
Atorvastatin Calcium198$1,661
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,604
Rosuvastatin Calcium61$1,363
Albuterol Sulfate HfaAlbuterol Sulfate35$737
Esomeprazole Magnesium16$720
Metoprolol Succinate47$640
Omeprazole51$564
Escitalopram Oxalate36$563
Pravastatin Sodium33$561
Pantoprazole Sodium25$509
Lisinopril93$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$28,93819 claims
PfizerEliquis$51$16,09523 claims
Lilly USA, LLCMounjaro$32$11,24711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,843 family providers in Maryland.

Other family in Manchester

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →